| Project/Area Number |
19390508
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
UZAWA Katsuhiro Chiba University, 大学院・医学研究院, 准教授 (30302558)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIRASAWA Hiroshi 千葉大学, 大学院・医学研究院, 教授 (00216194)
SHIIBA Masashi 千葉大学, 大学院・医学研究院, 講師 (20301096)
BUKAWA Hiroki 筑波大学, 医学部・臨床医学系, 教授 (80173558)
SAITO Kengo 千葉大学, 大学院・医学研究院, 助教 (70451755)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2009: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2008: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2007: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
|
|---|
| Keywords | 臨床腫瘍学 / 低病原性ウイルス / ウイルスカプシド / 腫瘍特異的吸着 / リポソーム / 腫瘍特異性 / リボソーム / drug delivery system / シンドビスウイルス |
|---|
| Research Abstract |
Targeted liposomes can be broadly defined as liposomes that are engineered to interact with a particular population of cells with the objective of delivering a payload or increasing their retention within the targeted cell population. We previously identifided a Sindbis virus (SIN) strain which preferentially infects several cancers in vitro and in vivo without side effects. In this study, we have developed a cisplatin-encapsulating cancer-targeted liposome with the SIN protein and evaluated its cytotoxicity to cancers in vitro and in vivo. In vitro, the cisplatin-encapsulating cancer-targeted liposome has exhibited higher cytotoxicity to cancer cells than the cisplatin-encapsulating non-targeted liposome. Mice injected with the cisplatin-encapsulating cancer-targeted liposome displayed rapid tumor regression. Thus, this finding that a cisplatin-encapsulating cancer-targeted liposome with the SIN protein selectively fused with cancer cells and sensitized cancer cells suggested the application of this cancer-targeted lipsome to cancer therapy.
|
